Comparative Pharmacology
Head-to-head clinical analysis: BALZIVA 28 versus CYCLAFEM 1 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BALZIVA 28 versus CYCLAFEM 1 35.
BALZIVA-28 vs CYCLAFEM 1/35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BALZIVA-28 is a combination estrogen-progestin oral contraceptive. Ethinyl estradiol provides estrogenic activity, while levonorgestrel acts as a progestin, primarily suppressing gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, and causing changes in cervical mucus and endometrium to reduce sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
One tablet (0.5 mg levonorgestrel and 0.1 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
None Documented
None Documented
2.5 hours; clinically relevant for dosing interval in renal impairment
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Renal: 50-60% as unchanged drug; fecal: 30-40% as metabolites; biliary: <5%
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive